HART KD a Highly Accurate, Artificial Intelligence-driven Blood Test for Kawasaki Disease

September 17, 2020

A highly, artificial intelligence-driven blood test for Kawasaki Disease, HART KD has been developed by Prevencio, Inc. The news was announced today. The company collaborated with Seattle Children’s Research Institute and leveraged its Artificial Intelligence (AI)-driven HART platform and expertise in developing cardiac blood tests.

Kawasaki disease is a rare but fatal childhood disease that causes inflammation in the walls of arteries throughout the body. It occurs mostly in children younger than 5 years old. Previously, there were no specific tests available for diagnosis. Experts like Dr. Michael Portman from Seattle Children’s Hospital believe that COVID-19 is triggering Kawasaki disease in some cases.

“Among the main presenting symptoms of Kawasaki disease are persistent fever and rash. This makes diagnosis challenging as thousands of children with these symptoms present annually to U.S. emergency departments,” stated Michael Portman, MD, director of pediatric cardiovascular research at Seattle Children’s and professor of pediatrics at the University of Washington School of Medicine. “With COVID-19-associated Multisystem Inflammatory Syndrome in Children (MIS-C), diagnosis of Kawasaki disease has become even more challenging and critical as the two have similar presenting symptoms, and it remains unclear whether Kawasaki disease can be triggered by the COVID virus.”

Without early treatment, Kawasaki disease can cause an increased risk of coronary (heart) artery dilation and aneurysms (ballooning), leading to the need for lifelong therapy and cardiac interventions.

“Before this, there was no specific diagnostic test for Kawasaki disease,” Portman added. “We are excited with the robust accuracy of HART KD and appreciate our collaboration with Prevencio to address this critical, unmet medical need.”

Prevencio used their long-standing, certified laboratory partner, Myriad RBM, to conduct protein measurements on blood samples collected from children with Kawasaki disease and is developing commercial options for offering HART KD for children suspected of Kawasaki disease.

“We are pleased to collaborate with Seattle Children’s Research Institute, one of the nation’s top five pediatric research centers,” stated Rhonda Rhyne, Prevencio’s chief executive officer. “We are excited to expand use of our AI Hart platform to Kawasaki disease and to be at the forefront of treating COVID-related medical issues. Prevencio retains world-wide exclusive rights and is exploring protein-measuring platforms and licensing partnerships to distribute HART KD.”

Medical Device News Magazinehttps://infomeddnews.com
Medical Device News Magazine provides our readership with breaking medical device / biotechnology news. Our subscribers include medical specialists, device industry executives, investors, and other allied health professionals, as well as patients who are interested in researching various medical devices. We hope you find value in our easy-to-read publication and its overall objectives! Medical Device News Magazine is a division of PTM Healthcare Marketing, Inc. Pauline T. Mayer is the managing editor.

More News!

The Thermo Scientific™ Dionex™ Inuvion™ Ion Chromatography (IC) system, helping to make ion analysis simpler and more intuitive for labs of all sizes. The new analytical instrument is designed to be easily reconfigurable, providing those who require determination of ionic and small polar compounds with a one stop shop for consistent, reliable ion analysis.
This new collaboration is another example of Blacksmith's creative deal-making with top tier partners that bring expertise to the table which helps de-risk and accelerate scientific discoveries for the development of valuable products.
Heparin Sodium 2,000 units in 0.9% Sodium Chloride Injection 1,000 mL (2 units/mL), is indicated as an anticoagulant to maintain catheter patency.
Through this agreement, RaySearch acquires full ownership of all rights to the product DrugLog for its application in the field of oncology, including the measuring device, calibration parameters, source code, as well as intellectual property rights.
Anna Kazanchyan, MD, Founder and CEO of Saghmos Therapeutics. "We are very pleased to announce the Notice of Allowance for our second patent, which will enhance the long-term value of ST-62516. Saghmos continues to build its intellectual property estate."

By using this website you agree to accept Medical Device News Magazine Privacy Policy